Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.
about
Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014A Review of the Key Clinical Trials of 2015: Results and ImplicationsLong-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials.Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion.Long term health outcomes in patients with a history of myocardial infarction: A population based cohort studyLong-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting.Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach?Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction.Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).Oral dual antiplatelet therapy: what have we learnt from recent trials?Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies.Dual antiplatelet therapy duration in patients following percutaneous coronary intervention or after acute coronary syndrome: one size does not fit all.The year in cardiology 2015: coronary intervention.The Tradeoff Between Shorter and Longer Courses of Dual Antiplatelet Therapy After Implantation of Newer Generation Drug-Eluting Stents.Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease.Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.Percutaneous Coronary Intervention: 2015 in Review.Late breaking trials of 2015 in coronary artery disease: Commentary covering ACC, EuroPCR, SCAI, TCT, ESC, and AHA.Systematic review of the clinical impact of dual antiplatelet therapy discontinuation after acute coronary syndromes.Which long-term antiplatelet regimen for patients with acute coronary syndromes?Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction.Dual antiplatelet therapy after coronary stenting.Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.An Updated Protocol for Evaluating Chest Pain and Managing Acute Coronary Syndromes.Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study.Drug-Eluting Stents Versus Bare Metal Stents for Percutaneous Coronary Intervention in Kidney Transplant Recipients.Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.Dual antiplatelet therapy duration after drug-eluting stents: how long?Should we reconsider dual antiplatelet therapy duration following bioresorbable scaffold angioplasty?Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome.Roles of ST2, IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention.Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma.Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials?The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.
P2860
Q26785321-C99A306C-E3F6-4F25-90A4-2BF1FC44469BQ28077170-DA474131-DC55-4AA5-B81E-CF72F44D0247Q30248679-0CA50FC7-B6F4-4D7C-BD36-80B3F97669D3Q31155795-6976E6F7-8BFA-4510-A5BE-48868A2203EAQ33613297-D1AF2FA1-1EF7-4FEE-AE00-B2050443C96AQ33642986-7ED68A10-603B-4DF9-9FDB-CCBE5D0D6E09Q33898330-7986C223-0BE4-4618-83BE-28BD60FC3CA1Q36081846-B35DEA17-C1CE-45FB-8215-D819DCA3B395Q36245021-F46D3301-6D5E-4D8C-9019-BAD9C3FBE8F0Q36706382-348BDFDF-E1A2-4425-9A00-F8EDE363AC68Q38379410-60FC7965-92A8-43F4-AD0D-23FAE9DAFF62Q38380436-301793EF-DD43-4E81-87D2-B558278CD63FQ38561878-711A4A53-1605-4B19-BC9A-839D7E4000D5Q38577755-162A7203-015D-449E-AC00-6C676238F19FQ38592772-52D424FD-D5A6-4A08-B6D4-46E2FB8E10BDQ38635747-4F31F060-4E02-4572-93E0-9E60D07534E0Q38676856-55085C5D-11B2-4EEC-BF32-4A8BA9930C79Q38685684-2CE49A90-2D59-44D6-9311-4C3BA4F8AB67Q38687494-986D78D7-DC5A-494A-9F07-4D16403EB9D5Q38692636-C9FB65D9-D349-4EED-8891-CC4FAEA911CCQ38726573-3EA17F89-7E2B-4F81-AF49-3D54B5179A5AQ38728869-67FC8A41-266F-4F7C-A84A-E80F8414CED9Q38762240-BD95A661-ADCA-491F-B189-00B57FC2A175Q38824526-45CFF9DD-85C9-4F74-B95E-A8C91C5A62F5Q38837527-A874E915-F398-4A29-9E28-A4AD1368A3D1Q38859458-03B4E98D-5F65-4227-801D-41BB725435B7Q38866836-1B2F6BC2-EFF8-4E53-A059-500032E96148Q38950967-BA318BBA-0E67-42F2-97FE-BB7448F3BA35Q38962250-08B96A62-94E5-4E23-B8BA-B516B4B8C4ACQ39154873-B182EBFA-4514-4C55-9C7A-1D9C2B84310EQ39495930-7C6C39A3-539A-4AD0-A2C5-6006E3ED7E94Q40813898-4EC01F3B-6EA0-4382-8309-A877AA517E53Q41111747-8648F4A8-E81C-4417-A278-E90BC6F9700AQ42362377-785BC936-90BB-4156-8292-C45D43BBF6CAQ44888352-3C13BB35-C059-402E-A9AE-882FD5159827Q46327219-2DBC7792-DD9A-4A80-917C-4A86BDC3FCFEQ47095088-58DC9199-46E2-4892-9B73-D690198483F2Q47624810-ABB90F07-B654-4D40-820F-3E8241370D84Q47691417-40ECAD69-82CF-4340-83FF-0B4BA3E8383BQ47865745-BE075A91-7B79-4F4C-94D2-AFB22519CFE7
P2860
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Benefits and Risks of Extended ...... t Acute Myocardial Infarction.
@ast
Benefits and Risks of Extended ...... t Acute Myocardial Infarction.
@en
type
label
Benefits and Risks of Extended ...... t Acute Myocardial Infarction.
@ast
Benefits and Risks of Extended ...... t Acute Myocardial Infarction.
@en
prefLabel
Benefits and Risks of Extended ...... t Acute Myocardial Infarction.
@ast
Benefits and Risks of Extended ...... t Acute Myocardial Infarction.
@en
P2093
P2860
P1476
Benefits and Risks of Extended ...... t Acute Myocardial Infarction.
@en
P2093
Adrian C Iancu
Alice Jacobs
Anthony H Gershlick
DAPT Study Investigators
David J Cohen
Dean J Kereiakes
Donald E Cutlip
Jean-Francois Tanguay
Joseph M Massaro
Laura Mauri
P2860
P304
P356
10.1016/J.JACC.2015.03.003
P407
P577
2015-03-15T00:00:00Z